-
1
-
-
65349135347
-
Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma
-
19318493 10.1158/1078-0432.CCR-08-2914
-
Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009;15:2905-12.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2905-2912
-
-
Li, Y.X.1
Liu, Q.F.2
Fang, H.3
-
2
-
-
51649091675
-
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
-
18626005 10.1200/JCO.2008.16.4558
-
Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-30.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4124-4130
-
-
Vose, J.1
Armitage, J.2
Weisenburger, D.3
-
3
-
-
53549130011
-
Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type
-
18756548 10.1002/ajh.21256
-
Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83:795-9.
-
(2008)
Am J Hematol
, vol.83
, pp. 795-799
-
-
Wang, B.1
Li, X.Q.2
Ma, X.3
-
4
-
-
81755172136
-
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell tumor study group study
-
21990393 10.1200/JCO.2011.35.6287 1:CAS:528:DC%2BC38Xns1Sgsw%3D%3D
-
Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell tumor study group study. J Clin Oncol. 2011;29(33):4410-6.
-
(2011)
J Clin Oncol
, vol.29
, Issue.33
, pp. 4410-4416
-
-
Yamaguchi, M.1
Kwong, Y.L.2
Kim, W.S.3
-
5
-
-
79951483189
-
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
-
21123825 10.1182/blood-2010-09-307454 1:CAS:528:DC%2BC3MXisFKqs7s%3D
-
Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834-9.
-
(2011)
Blood
, vol.117
, Issue.6
, pp. 1834-1839
-
-
Jaccard, A.1
Gachard, N.2
Marin, B.3
-
6
-
-
84872087371
-
First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma
-
22811078 10.1002/cncr.27752 1:CAS:528:DC%2BC3sXjs1yqtg%3D%3D
-
Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348-55.
-
(2013)
Cancer
, vol.119
, pp. 348-355
-
-
Wang, L.1
Wang, Z.H.2
Chen, X.Q.3
-
7
-
-
28444438522
-
E extranodal NK/T-cell lymphoma, nasal type
-
DOI 10.1182/blood-2005-05-2056
-
Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than international prognostic index in stage I (E)/II (E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106:3785-90. (Pubitemid 41739013)
-
(2005)
Blood
, vol.106
, Issue.12
, pp. 3785-3790
-
-
Tae, M.K.1
Yeon, H.P.2
Lee, S.-Y.3
Kim, J.-H.4
Kim, D.-W.5
Im, S.-A.6
Kim, T.-Y.7
Chul, W.K.8
Dae, S.H.9
Bang, Y.-J.10
Chang, K.-H.11
Noe, K.K.12
-
8
-
-
33644843494
-
Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study
-
DOI 10.1200/JCO.2005.04.1384
-
Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasaltype: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612-8. (Pubitemid 46630424)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.4
, pp. 612-618
-
-
Lee, J.1
Suh, C.2
Yeon, H.P.3
Ko, Y.H.4
Soo, M.B.5
Jae, H.L.6
Dae, H.L.7
Huh, J.8
Sung, Y.O.9
Kwon, H.-C.10
Hyo, J.K.11
Soon, I.L.12
Jung, H.K.13
Park, J.14
Seok, J.O.15
Kim, K.16
Jung, C.17
Park, K.18
Won, S.K.19
-
9
-
-
84872183512
-
Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients
-
22983648 10.1007/s12185-012-1174-y 1:CAS:528:DC%2BC38XhslClu73K
-
Wang L, Xia ZJ, Huang HQ, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 2012;96:617-23.
-
(2012)
Int J Hematol
, vol.96
, pp. 617-623
-
-
Wang, L.1
Xia, Z.J.2
Huang, H.Q.3
-
10
-
-
84867810745
-
SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia lymphoma study group
-
22919026 10.1182/blood-2012-05-431460 1:CAS:528:DC%2BC38XhsFKku7rN
-
Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(15):2973-80.
-
(2012)
Blood
, vol.120
, Issue.15
, pp. 2973-2980
-
-
Kwong, Y.L.1
Kim, W.S.2
Lim, S.T.3
-
11
-
-
82955217787
-
Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type
-
21984805 10.1182/blood-2011-05-354142 1:CAS:528:DC%2BC3MXhs1ansbzL
-
Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018-22.
-
(2011)
Blood
, vol.118
, pp. 6018-6022
-
-
Suzuki, R.1
Yamaguchi, M.2
Izutsu, K.3
-
12
-
-
84865000830
-
Serum beta2-microglobin is a predictor of prognosis in patients with upper aero digestive tract NK/T-cell lymphoma
-
22373550 10.1007/s00277-012-1434-1 1:CAS:528:DC%2BC38XhtVSlsLjP
-
Li ZM, Zhu YJ, Sun J, et al. Serum beta2-microglobin is a predictor of prognosis in patients with upper aero digestive tract NK/T-cell lymphoma. Ann Hematol. 2012;91(8):1265-70.
-
(2012)
Ann Hematol
, vol.91
, Issue.8
, pp. 1265-1270
-
-
Li, Z.M.1
Zhu, Y.J.2
Sun, J.3
-
13
-
-
38149076482
-
Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: A review
-
17906988 10.1080/13547500701674063 1:CAS:528:DC%2BD1cXksVKktA%3D%3D
-
Bien E, Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 2008;13(1):1-26.
-
(2008)
Biomarkers
, vol.13
, Issue.1
, pp. 1-26
-
-
Bien, E.1
Balcerska, A.2
-
14
-
-
0025779931
-
Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma
-
1848475 10.1002/1097-0142(19910415)67:8<2180: AID-CNCR2820670829>3. 0.CO;2-T 1:STN:280:DyaK3M7mvVWitA%3D%3D
-
Lai KN, Ho S, Leung JC, Tsao SY. Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. Cancer. 1991;67(8):2180-5.
-
(1991)
Cancer
, vol.67
, Issue.8
, pp. 2180-2185
-
-
Lai, K.N.1
Ho, S.2
Leung, J.C.3
Tsao, S.Y.4
-
15
-
-
0027955854
-
Progression mechanisms in colon cancer: Soluble interleukin-2 (IL-2) receptor; IL-2 plus anti-CD3 proliferative response and tumor stage correlations
-
Berghella AM, Pellegrini P, Piancatelli D, et al. Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother. 1994;38(3):160-6. (Pubitemid 24069224)
-
(1994)
Cancer Immunology Immunotherapy
, vol.38
, Issue.3
, pp. 160-166
-
-
Berghella, A.M.1
Pellegrini, P.2
Piancatelli, D.3
Maccarone, D.4
Del Beato, T.5
Giubilei, D.6
Pomidori, A.7
Adorno, D.8
Casciani, C.U.9
-
16
-
-
0025777606
-
Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour
-
2044083 10.1007/BF01756142 1:STN:280:DyaK3M3ls1aisw%3D%3D
-
Sharma S, Saha K, Shinghal RN, Malik GB. Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour. Cancer Immunol Immunother. 1991;33(3):198-202.
-
(1991)
Cancer Immunol Immunother
, vol.33
, Issue.3
, pp. 198-202
-
-
Sharma, S.1
Saha, K.2
Shinghal, R.N.3
Malik, G.B.4
-
17
-
-
0027459983
-
High serum and ascitic soluble interleukin-2 receptor α levels in advanced epithelial ovarian cancer
-
Barton DP, Blanchard DK, Michelini-Norris B, et al. High serum and ascitic soluble interleukin-2 receptor a levels in advanced epithelial ovarian cancer. Blood. 1993;81(2):424-9. (Pubitemid 23027160)
-
(1993)
Blood
, vol.81
, Issue.2
, pp. 424-429
-
-
Barton, D.P.J.1
Blanchard, D.K.2
Michelini-Norris, B.3
Nicosia, S.V.4
Cavanagh, D.5
Djeu, J.Y.6
-
18
-
-
0031750176
-
Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer
-
Nakata B, Chung KH, Kato Y, et al. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer. 1998;77(11):1820-4. (Pubitemid 28254617)
-
(1998)
British Journal of Cancer
, vol.77
, Issue.11
, pp. 1820-1824
-
-
Nakata, B.1
Hirakawa, K.2
Chung, Y.S.3
Kato, Y.4
Yamashita, Y.5
Inui, A.6
Arimoto, Y.7
Maeda, K.8
Onoda, N.9
Sawada, T.10
Sowa, M.11
-
19
-
-
0025764781
-
Soluble interleukin 2 receptor in lung cancer: An indirect marker of tumor activity?
-
2036827 10.1378/chest.99.6.1433 1:STN:280:DyaK3M3ktlCntA%3D%3D
-
Buccheri G, Marino P, Preatoni A, et al. Soluble interleukin 2 receptor in lung cancer: an indirect marker of tumor activity? Chest. 1991;99(6):1433-7.
-
(1991)
Chest
, vol.99
, Issue.6
, pp. 1433-1437
-
-
Buccheri, G.1
Marino, P.2
Preatoni, A.3
-
20
-
-
0023944398
-
Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia
-
3128348 1:STN:280:DyaL1c7osVWqtg%3D%3D
-
Pui CH, Ip SH, Iflah S, et al. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood. 1988;71(4):1135-7.
-
(1988)
Blood
, vol.71
, Issue.4
, pp. 1135-1137
-
-
Pui, C.H.1
Ip, S.H.2
Iflah, S.3
-
21
-
-
34547691044
-
Hemophagocytic syndromes
-
DOI 10.1016/j.blre.2007.05.001, PII S0268960X07000240
-
Janka G. Hemophagocytic syndromes. Blood Rev. 2007;21:245-53. (Pubitemid 47212601)
-
(2007)
Blood Reviews
, vol.21
, Issue.5
, pp. 245-253
-
-
Janka, G.E.1
-
22
-
-
0025034736
-
Peripheral T-cell lymphoma associated with hemophagocytic syndrome
-
Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood. 1990;75(2):434-44. (Pubitemid 20035275)
-
(1990)
Blood
, vol.75
, Issue.2
, pp. 434-444
-
-
Falini, B.1
Pileri, S.2
De Solas, I.3
Martelli, M.F.4
Mason, D.Y.5
Delsol, G.6
Gatter, K.C.7
Fagioli, M.8
-
23
-
-
33845619137
-
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
-
DOI 10.1002/pbc.21039
-
Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-31. (Pubitemid 44958267)
-
(2007)
Pediatric Blood and Cancer
, vol.48
, Issue.2
, pp. 124-131
-
-
Henter, J.-I.1
Horne, A.2
Arico, M.3
Egeler, R.M.4
Filipovich, A.H.5
Imashuku, S.6
Ladisch, S.7
McClain, K.8
Webb, D.9
Winiarski, J.10
Janka, G.11
-
24
-
-
61349149366
-
Extranodal NK/T-cell lymphoma, nasal type
-
S.H. Swerdlow E. Campo N.L. Harris (eds) et al. IARC Lyon
-
Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. p. 285-8.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 285-288
-
-
Chan, J.K.1
Quintanilla-Martinez, L.2
Ferry, J.A.3
Peh, S.-C.4
-
25
-
-
79957516735
-
Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: A single-institution experience
-
21599590 10.3109/10428194.2011.561388 1:CAS:528:DC%2BC3MXmtl2msbg%3D
-
Huang H, Lin Z, Lin X, et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma. 2011;52:1041-8.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 1041-1048
-
-
Huang, H.1
Lin, Z.2
Lin, X.3
-
26
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group
-
10561185 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D
-
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol. 1999;17:1244.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
-
27
-
-
0034007146
-
Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma
-
Wang Liang-Shun, Chow Kuan-Chih, Li Wing-Yin, et al. Clinical significance of serum soluble interleukin 2 receptor-a in esophageal squamous cell carcinoma. Clin Cancer Res. 2000;6:1445-51. (Pubitemid 30226233)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.4
, pp. 1445-1451
-
-
Wang, L.-S.1
Chow, K.-C.2
Li, W.-Y.3
Liu, C.-C.4
Wu, Y.-C.5
Huang, M.-H.6
-
28
-
-
32844470593
-
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma
-
DOI 10.1038/sj.jid.5700122, PII 5700122
-
Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(3):575-83. (Pubitemid 43255644)
-
(2006)
Journal of Investigative Dermatology
, vol.126
, Issue.3
, pp. 575-583
-
-
Talpur, R.1
Jones, D.M.2
Alencar, A.J.3
Apisarnthanarax, N.4
Herne, K.L.5
Yang, Y.6
Duvic, M.7
-
29
-
-
0023907493
-
Interleukin-2: Inception, impact, and implications
-
3131876 10.1126/science.3131876 1:CAS:528:DyaL1cXkt1Whtrs%3D
-
Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169-76.
-
(1988)
Science
, vol.240
, pp. 1169-1176
-
-
Smith, K.A.1
-
30
-
-
0022536230
-
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes
-
3008337 10.1126/science.3008337 1:CAS:528:DyaL2sXjs1ar
-
Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986;232:727-32.
-
(1986)
Science
, vol.232
, pp. 727-732
-
-
Waldmann, T.A.1
-
31
-
-
0028361965
-
Differential expression of interleukin-2 receptors (α and β chain) in mature lymphoid neoplasms
-
DOI 10.1002/ajh.2830460304
-
Nakase K, Kita K, Nasu K, et al. Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol. 1994;46:179-83. (Pubitemid 24206741)
-
(1994)
American Journal of Hematology
, vol.46
, Issue.3
, pp. 179-183
-
-
Nakase, K.1
Kita, K.2
Nasu, K.3
Ueda, T.4
Tanaka, I.5
Shirakawa, S.6
Tsudo, M.7
-
32
-
-
0025077169
-
The soluble interleukin-2 receptor: Biology, function, and clinical application
-
Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113:619-27. (Pubitemid 20346191)
-
(1990)
Annals of Internal Medicine
, vol.113
, Issue.8
, pp. 619-627
-
-
Rubin, L.A.1
Nelson, D.L.2
-
33
-
-
61649088127
-
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
-
19074749 10.1093/annonc/mdn677 1:STN:280:DC%2BD1M7mvVajsg%3D%3D
-
Ennishi D, Yokoyama M, Terui Y, et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol. 2009;20:526-33.
-
(2009)
Ann Oncol
, vol.20
, pp. 526-533
-
-
Ennishi, D.1
Yokoyama, M.2
Terui, Y.3
-
34
-
-
80052623454
-
Soluble IL-2R alpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma
-
21719603 10.1182/blood-2011-03-340885 1:CAS:528:DC%2BC3MXht1ansL3P
-
Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble IL-2R alpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood. 2011;118:2809-20.
-
(2011)
Blood
, vol.118
, pp. 2809-2820
-
-
Yang, Z.Z.1
Grote, D.M.2
Ziesmer, S.C.3
-
35
-
-
0035141983
-
A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma
-
DOI 10.1034/j.1600-0609.2001.00334.x
-
Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2001;66:24-30. (Pubitemid 32099406)
-
(2001)
European Journal of Haematology
, vol.66
, Issue.1
, pp. 24-30
-
-
Niitsu, N.1
Iijima, K.2
Chizuka, A.3
-
36
-
-
84862791825
-
Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: A comprehensive clinicopathologic and phenotypic study
-
22314189 10.1097/PAS.0b013e31824433d8
-
Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36(4):481-99.
-
(2012)
Am J Surg Pathol
, vol.36
, Issue.4
, pp. 481-499
-
-
Pongpruttipan, T.1
Sukpanichnant, S.2
Assanasen, T.3
-
37
-
-
84880717292
-
Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma
-
23747081 10.1016/j.clml.2013.03.014 1:CAS:528:DC%2BC3sXptFGms7s%3D
-
Yoshizato T, Nannya Y, Imai Y, et al. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13(4):410-6.
-
(2013)
Clin Lymphoma Myeloma Leuk
, vol.13
, Issue.4
, pp. 410-416
-
-
Yoshizato, T.1
Nannya, Y.2
Imai, Y.3
-
38
-
-
51449098773
-
Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis
-
18615554 10.1002/ajh.21236 1:CAS:528:DC%2BD1cXhtF2qsr7M
-
Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008;83(9):747-9.
-
(2008)
Am J Hematol
, vol.83
, Issue.9
, pp. 747-749
-
-
Olin, R.L.1
Nichols, K.E.2
Naghashpour, M.3
|